Tecoro Bio Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
14
Tecoro Bio General Information
Description
Developer of biopharmaceutical products designed for the treatment of dermatologic diseases. The company develops small-molecule drug candidates utilizing selective inhibitors and thyromimetics for topical administration, enabling the healthcare sector to provide targeted therapies for skin disorders with minimal systemic exposure.
Contact Information
Website
www.tkskin.comCorporate Office
- Room 1401, Building 2, Number 18, Section 2
- Bio-City Middle Road, Shuangliu District
- Chengdu, Sichuan 610219
- China
Corporate Office
- Room 1401, Building 2, Number 18, Section 2
- Bio-City Middle Road, Shuangliu District
- Chengdu, Sichuan 610219
- China
Tecoro Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 15-Jan-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 08-May-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series A1) | 11-Oct-2022 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 27-Oct-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A) | 07-Apr-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 18-Sep-2018 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 26-Jul-2018 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 29-Nov-2016 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 20-May-2016 | Completed | Generating Revenue |
Tecoro Bio Patents
Tecoro Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4745127-A1 | Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof | Pending | 13-Jul-2023 | ||
| EP-4745131-A1 | Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof | Pending | 13-Jul-2023 | ||
| WO-2025011444-A1 | Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof | Inactive | 13-Jul-2023 | ||
| WO-2025011446-A1 | Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof | Inactive | 13-Jul-2023 | ||
| EP-4745132-A1 | Pyrimidinamine nuak inhibitor, and preparation method therefor and use thereof | Pending | 13-Jul-2023 | C07D401/14 |
Tecoro Bio Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Viva Ventures Biotech Group | Venture Capital | Minority | ||
| Zoo Capital | Venture Capital | Minority | ||
| Hiway Capital | Venture Capital | Minority | ||
| Chengdu Bio-Town Investment | Government | Minority | ||
| Orinno Capital | Venture Capital | Minority |
Tecoro Bio FAQs
-
When was Tecoro Bio founded?
Tecoro Bio was founded in 2014.
-
Where is Tecoro Bio headquartered?
Tecoro Bio is headquartered in Chengdu, China.
-
What industry is Tecoro Bio in?
Tecoro Bio’s primary industry is Drug Discovery.
-
Is Tecoro Bio a private or public company?
Tecoro Bio is a Private company.
-
What is Tecoro Bio’s current revenue?
The current revenue for Tecoro Bio is .
-
How much funding has Tecoro Bio raised over time?
Tecoro Bio has raised $15.4M.
-
Who are Tecoro Bio’s investors?
Viva Ventures Biotech Group, Zoo Capital, Hiway Capital, Chengdu Bio-Town Investment, and Orinno Capital are 5 of 14 investors who have invested in Tecoro Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process